{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Carey KA"],"funding":["National Institute of Allergy and Infectious Diseases","Intramural NIH HHS","U.S. Department of Energy","Oak Ridge Institute for Science and Education","National Institutes of Health"],"pagination":["7176-7181"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11261575"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(50)"],"pubmed_abstract":["<h4>Background</h4>Neisseria gonorrhoeae cross-protection was suggested in a New Zealand meningitis B vaccine. We modeled the potential impact of similar vaccines on gonorrhea prevalence in heterosexuals in the United States.<h4>Methods</h4>Our mathematical model incorporated infection, behavior, and vaccination dynamics. Approximate Bayesian Computation calibrated our model to US prevalence. Primary analyses assumed New Zealand vaccine characteristics: 30% efficacy and 2-year duration of protection. We estimated impact under two vaccine coverages (20%, 50%).<h4>Results</h4>Reduction in gonorrhea prevalence ranged from 4.8 to 39.4%, depending on vaccine coverage. Vaccine impact was correlated with both size of the highly sexually active subpopulation and sexual mixing between high and low "],"journal":["Vaccine"],"pubmed_title":["Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model."],"pmcid":["PMC11261575"],"funding_grant_id":["Z99 AI999999"],"pubmed_authors":["Carey KA","Newman LM","Spicknall IH"],"additional_accession":[]},"is_claimable":false,"name":"Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model.","description":"<h4>Background</h4>Neisseria gonorrhoeae cross-protection was suggested in a New Zealand meningitis B vaccine. We modeled the potential impact of similar vaccines on gonorrhea prevalence in heterosexuals in the United States.<h4>Methods</h4>Our mathematical model incorporated infection, behavior, and vaccination dynamics. Approximate Bayesian Computation calibrated our model to US prevalence. Primary analyses assumed New Zealand vaccine characteristics: 30% efficacy and 2-year duration of protection. We estimated impact under two vaccine coverages (20%, 50%).<h4>Results</h4>Reduction in gonorrhea prevalence ranged from 4.8 to 39.4%, depending on vaccine coverage. Vaccine impact was correlated with both size of the highly sexually active subpopulation and sexual mixing between high and low ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T14:46:03.367Z","creation":"2025-04-04T14:46:03.367Z"},"accession":"S-EPMC11261575","cross_references":{"pubmed":["36333224"],"doi":["10.1016/j.vaccine.2022.10.031"]}}